Company
MeiraGTx
MeiraGTx has 14 drugs tracked on RxWires: 4 in Phase 3, 2 in Phase 2, 6 in Phase 1/2, 2 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Genetic: AAV5-hRKp.RPGR Intermediate Dose | Phase 3 | X-Linked Retinitis Pigmentosa |
| Genetic: AAV5-hRKp.RPGR | Phase 3 | X-Linked Retinitis Pigmentosa |
| Toremifene | Phase 3 | Risk of Bone Fracture Occurrences |
| AAV5-hRKp.RPGR | Phase 3 | Retinitis Pigmentosa |
| AAV2-hAQP1 | Phase 2 | Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands |
| AAV2-hAQP1 Concentration 1 | Phase 2 | Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands |
| AAV-GAD Low Dose | Phase 1/2 | Parkinson's Disease |
| AAV-GAD | Phase 1/2 | Parkinson's Disease |
| AAV - CNGB3 | Phase 1/2 | Achromatopsia |
| AAV RPE65 | Phase 1/2 | Leber Congenital Amaurosis |
| AAV5-RPGR | Phase 1/2 | X-Linked Retinitis Pigmentosa |
| adeno-associated virus vector AAV- CNGA3 | Phase 1/2 | Achromatopsia |
| AAV2hAQP1: 1 x 10^11 vg/gland (single gland) | Phase 1 | Radiation-Induced Parotid Gland Hypofunction |
| AAV2hAQP1 | Phase 1 | Squamous Cell Head and Neck Cancer |
Latest
Follow MeiraGTx on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.